Adverse Event Reporting
| VAERS ID | 1276401 |
|---|---|
| Gender | Female |
| Age | |
| StateCode | |
| Pharmaceutical Company | JANSSEN |
| Lot Number | |
| Number of vaccinations | |
| Vaccinated | |
| Onset | 2021-03-20 |
| Condition | Hospitalized Permanent Disability |
Symptoms
- Blindness
- Visual acuity reduced
- Retinal artery occlusion
Current Illness
Preexisting Conditions
Comments: Unknown
Other Medications
Previous Vaccinations
Allergies
Laboratory Data
Write-up
BLINDNESS; RETINAL ARTERY OCCLUSION; VISUAL ACUITY REDUCED; This spontaneous report received from a healthcare professional via VAERS (Vaccine Adverse Event Reporting System, VAERS ID 1201402-1) concerned an 82 year old female.
Initial information was processed with additional information received from VAERS on 23-APR-2021.
The patient's weight, height, and medical history were not reported.
The patient received covid-19 vaccine ad26.
cov2.
s (suspension for injection, intramuscular, batch number: Unknown) dose and anatomical vaccination site was not reported, administered on 06-MAR-2021 for prophylactic vaccination.
The batch number was not reported.
The Company is unable to perform follow-up to request batch/lot numbers.
No concomitant medications were reported.
On 20-MAR-2021, the subject experienced blindness in both eyes, retinal artery occlusion and visual acuity reduced (no light perception in the right and counting fingers in the left).
She went to the emergency room and was hospitalized.
Work up for other causes (not further specified) was reported as negative.
The action taken with covid-19 vaccine ad26.
cov2.
s was not applicable.
The patient had not recovered from blindness in both eyes, retinal artery occlusion and visual acuity reduced.
This report was serious (Hospitalization Caused / Prolonged, Disability Or Permanent Damage).
; Sender's Comments: V0: This 82-year-old female patient of unspecified ethnicity was hospitalized for blindness in both eyes, retinal artery occlusion and visual acuity reduced (no light perception in the right and counting fingers in the left) 14 days after receiving COVID-19 VACCINE AD26.
COV2.
S for the prevention of symptomatic SARS-CoV-2 virus infection.
No other details reported.
The information available precludes a complete and meaningful assessment.
However, considering the temporal relationship and recently evolving theories in the literature about COVID infections and vaccinations, potential vaccine contribution cannot be excluded.
Additional information was requested.